Iron deficiency (ID) is the most common nutritional disorder worldwide. It is often observed in
patients with chronic diseases, such as heart failure (HF), chronic kidney disease (CKD) …

Plasma zinc concentrations are decreased in patients on hemodialysis; zinc
supplementation increases hemoglobin levels and reduces erythropoietin-stimulating agent …

Results Of 332 participants screened, 271 participants were randomized (safety evaluation:
271 participants; efficacy evaluation: 267 intent-to-treat population). The mean hemoglobin …

Background International variation in anemia assessment and management practices in
chronic kidney disease (CKD) is poorly understood. Methods We performed a cross …

In recent years, a concept of renal rehabilitation has become widely known among
nephrology specialists, dialysis specialists, kidney transplantation specialists, rehabilitation …

Background In patients on maintenance dialysis, cardiovascular mortality risk is remarkably
high, which can be partly explained by severe coronary artery calcification (CAC) …

Background Standard care for treating anemia in patients with CKD includes use of
erythropoiesis-stimulating agents, which sometimes involves increased risks of …

Background: Daprodustat is an oral agent that stimulates erythropoiesis by inhibiting the
prolyl hydroxylases which mark hypoxia-inducible factor for degradation through …

Abstract Introduction: Erythropoiesis-stimulating agents (ESAs) are the current standard of
care for anemia due to chronic kidney disease (CKD) in patients not undergoing dialysis …

Background Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis. Methods The efficacy and safety of vadadustat, compared with …